Free Trial
NASDAQ:CLDX

Celldex Therapeutics Q1 2025 Earnings Report

Celldex Therapeutics logo
$20.50 -0.32 (-1.54%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$19.93 -0.57 (-2.78%)
As of 06/20/2025 06:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Celldex Therapeutics EPS Results

Actual EPS
-$0.81
Consensus EPS
-$0.75
Beat/Miss
Missed by -$0.06
One Year Ago EPS
N/A

Celldex Therapeutics Revenue Results

Actual Revenue
$0.70 million
Expected Revenue
$1.08 million
Beat/Miss
Missed by -$384.00 thousand
YoY Revenue Growth
N/A

Celldex Therapeutics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 8, 2025
Conference Call Time
12:00AM ET

Upcoming Earnings

Celldex Therapeutics' Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Celldex Therapeutics Earnings Headlines

What is Lifesci Capital's Forecast for CLDX Q2 Earnings?
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Celldex Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Celldex Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Celldex Therapeutics and other key companies, straight to your email.

About Celldex Therapeutics

Celldex Therapeutics (NASDAQ:CLDX), a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

View Celldex Therapeutics Profile

More Earnings Resources from MarketBeat